Mutations in a protein phosphatase and a protein kinase cause hamartomatous polyposis syndromes, which are characterised by the formation of multiple benign polyps and an increased susceptibility to some types of cancer.
The identification of the molecular mechanisms involved in hereditary cancer syndromes has contributed much to our understanding of the molecular events underlying tumorigenesis. For example, familial adenomatous polyposis coli (FAP), a syndrome characterised by the formation of multiple benign polyps in the colon and rectum, from which tumours may develop if left untreated, is caused by mutation or deletion of the APC gene. Identification of APC as the gene involved in FAP has led to a greater understanding of the pathogenesis of colon cancer, and changes at the APC locus can be used as a marker to identify patients with a predisposition to colon cancer [7] .
A cell may progress towards oncogenic transformation when one allele of a tumour suppressor gene is inactivated, as a result either of an inherited germline mutation or an acquired somatic mutation. Inactivation of the second allele of the gene usually involves a somatic mutation or deletion, resulting in loss of heterozygosity. Loss of heterozygosity can thus provide an indication of the chromosomal localisation of tumour suppressor genes. A genetic alteration found frequently in a number of different human tumours is loss of heterozygosity at chromosome 10q23, which occurs in about 70% of glioblastomas -the most advanced form of glial tumour -and about 60% of advanced prostate cancers [8] . This led to suspicion that chromosome 10q23 encodes a tumour suppressor gene. Li et al. [8] recently identified a candidate tumour suppressor gene in this region which they termed PTEN, for 'phosphatase and tensin homologue deleted on chromosome ten'. The same gene was independently isolated by Steck et al. [9] , who called it MMAC1, for 'mutated in multiple advanced cancers 1', and by Li and Sun [10] , who termed it TEP1, for 'TGFβ-regulated and epithelial cell enriched phosphatase 1'. For simplicity, we shall refer to the gene as PTEN.
The PTEN protein shows sequence similarity to protein tyrosine phosphatases, and Myers et al. [11] have since demonstrated that PTEN is indeed a phosphatase, belonging to the subclass of dual-specificity enzymes that can dephosphorylate serine, threonine or tyrosine residues on target proteins. PTEN shows a high degree of substrate specificity in vitro, dephosphorylating only the most acidic peptide substrates tested [11] , although physiological targets of PTEN remain to be identified. A number of dual-specificity phosphatases show a preference for members of the MAP kinase family, but Myers et al. [11] found that PTEN is unable to dephosphorylate the MAP kinase ERK2 in vitro.
PTEN also exhibits extensive sequence homology along much of its length to the cytoskeletal protein tensin. Tensin is a Src-homology 2 (SH2) domain-containing protein which binds to actin and localises to focal adhesions, where it is thought to play a role in the assembly of signalling complexes. PTEN also has several potential phosphorylation sites, and a region at its carboxyl terminus that resembles a motif characteristic of binding sites for PDZ domains [12] . Interestingly, the APC protein also has a PDZ-binding domain, through which it interacts with the PDZ domain of the human homologue of the Drosophila 'discs large tumour suppressor' protein [13] . These features of PTEN suggest that it may have roles in addition to that of a phosphatase, perhaps acting as a docking protein in the assembly of multi-protein signalling complexes.
The PTEN locus is deleted or mutated, presumably somatically, in a significant number of tumours and tumour cell lines, including glioblastomas, malignant melanomas and prostate, breast and endometrial tumours [8, 9, [14] [15] [16] [17] . Interestingly, germline mutations in PTEN also cause Cowden disease (CD), a syndrome characterised by the formation of multiple, benign tumours (hamartomas) and increased susceptibility to tumours of the skin, thyroid and breast (Table 1) [18, 19] . Mutations in PTEN have also been identified in patients suffering from other hamartomatous polyposis syndromes similar to CD, such as Lhermitte-Duclos disease (LDD) and Bannayan-Zonana syndrome (BZS) [20] (Table 1 ). An identical PTEN mutation -C to T at codon 233 -has been identified in both a family with CD, and a family with BZS (Table 1 ). This mutation arose on two different 10q22-23 haplotypes [20] , arguing against a common ancestor or founder effect. The identification of the same mutation in these two unrelated families suggests that it may have pleiotropic effects. Alternatively, other factors, genetic or epigenetic, may be responsible for the phenotypic differences seen in the two disorders.
The genetic lesion responsible for a fourth hamartomatous polyposis syndrome, Juvenile polyposis syndrome (JPS), has been putatively localised to chromosome 10q22.3-q24.1 ( Table 1 ). The evidence implicating PTEN in this syndrome is somewhat controversial. Marsh et al. [21] excluded both PTEN and chromosome 10q22.3-q24.1 as the susceptibility locus for JPS; however, Lynch et al. [22] and Olschwang et al. [23] have identified PTEN mutations in some JPS patients. The PTEN mutations identified both in patients with these cancer predisposition syndromes, and in primary tumours, have been predicted to abolish, or significantly reduce, the phosphatase activity of PTEN. In a number of cases this has in fact been demonstrated [11] , indicating that the enzymatic activity of PTEN is necessary for its ability to act as a tumour suppressor, and suggesting that PTEN may suppress tumour cell growth by opposing the actions of protein kinases.
The family of hamartomatous polyposis syndromes to which CD, BZS and JPS belong also includes the Peutz-Jeghers syndrome (PJS). PJS is a rare, dominantly inherited condition, typified by the formation of intestinal hamartomatous polyps and mucocutaneous pigmentation affecting the lips, buccal mucosa and digits (Table 1) . Patients with PJS also have an increased susceptibility to tumours of the gastrointestinal tract, breast, testis and ovary. A locus for this condition was recently mapped to chromosome 19p. Hemminki et al. [24] have since R242 Current Biology, Vol 8 No 7 identified germline mutations in a gene residing on chromosome 19p in patients with PJS. This previously identified but unmapped gene, termed LKB1, encodes a serine/threonine kinase originally found to be expressed in human foetal liver. LKB1 exhibits strong sequence similarity to a Xenopus serine/threonine kinase, XEEK1 for 'Xenopus egg and embryo kinase' [25] . XEEK1 is a cytoplasmic kinase with a narrow substrate specificity, expressed in Xenopus oocytes and fertilised eggs but barely detectable during gastrulation and later embryonic stages. The mutations identified in LKB1 in patients with PJS are predicted to abolish some or all of the kinase activity of the protein, although this remains to be formally demonstrated.
That PTEN and LKB1 are mutated in hamartomatous polyposis syndromes may give some clue to the cellular roles of their products. As hamartomas are benign, disorganised masses of cells and tissues, PTEN and LKB1 may function in normal tissues to guide cellular interactions, ensuring that tissues and organs are correctly formed. Heterozygous mutation of PTEN or LKB1, in combination with loss of heterozygosity of the wild-type allele, might cause a tendency to proliferation and tissue disorganisation, leading to the formation of hamartomas. This aberrant proliferation and disorganisation may be the background on which malignant transformation then occurs as a result of somatic mutation of other tumour suppressor genes and/or oncogenes. It remains to be seen whether PTEN and LKB1 act in the same signal transduction pathway.
Despite the lack of available information on the actual functions and physiological substrates of the enzymes encoded by PTEN and LKB1, the recent evidence implicating them in the cancer predisposition syndromes CD, BZS, JPS and PJS should facilitate the early diagnosis of both familial and sporadic cases of these disorders. Determination of the normal cellular functions of the enzymes PTEN and LKB1 should also provide a greater understanding of the pathogenesis of the various tumours associated with these syndromes.
